Selpercatinib: Metastatic Ret Fusion

The medicine Retevmo contains Selpercatinib for treating patients with metastatic RET fusion-positive non-small cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid cancer. This medicine comes in 40 mg and 80 mg capsules to administer orally. The active ingredient in the medicine is Selpercatinib, with inactive ingredients microcrystalline cellulose and colloidal silicon dioxide.

One can buy Retevmo capsules from several generic medicine suppliers in India. To know more about Selpercainib, dial 1800-889-1064.

Source: https://www.indianpharmanetwork.in/retevmo-selpercatinib/